![]() ![]() Furthermore, the iPEX® HS chemistry stated in this manuscript was developed and launched by Agena Bioscience as a commercial product in 2016. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Ĭompeting interests: Agena Bioscience provided support in the form of salaries of authors RTB, JK, MM, DI, but did not have any additional role in the study design, data collection and analysis, decision to publish or preparation if the manuscript. Furthermore, the iPLEX® HS chemistry stated in this manuscript was developed and launched by Agena Bioscience as a commercial product in 2016. MSS was partially supported by grant funding from The Walther Cancer Foundation. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.ĭata Availability: All relevant data are within the paper and its Supporting Information files.įunding: Agena Bioscience provided support in the form of salaries for authors RTB, JK, MM, DI, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Received: MaAccepted: AugPublished: September 19, 2017Ĭopyright: © 2017 Sutton et al. PLoS ONE 12(9):Įditor: Giancarlo Troncone, Universita degli Studi di Napoli Federico II, ITALY (2017) Assessment of common somatic mutations of EGFR, KRAS, BRAF, NRAS in pulmonary non-small cell carcinoma using iPLEX ® HS, a new highly sensitive assay for the MassARRAY ® System. This highly sensitive system identified approximately 10% more KRAS, NRAS, EGFR and BRAF mutations than were detected by the original test platform, which had a sensitivity range of 5–10% variant allele frequency (VAF).Ĭitation: Sutton BC, Birse RT, Maggert K, Ray T, Hobbs J, Ezenekwe A, et al. In this study, we assessed 179 clinical cases of non-small cell lung carcinoma (NSCLC) that had been previously tested for EGFR, KRAS, NRAS, and BRAF mutations using a novel multiplexed analytic approach that reduces wild-type signal and allows for detection of low mutation load approaching 1%, iPLEX ® HS panel for the MassARRAY ® System (Agena Bioscience, San Diego, CA). However, use of these less invasive procedures generates significant analytical challenges for the laboratory, such as a requirement for robust detection of low level somatic mutations, particularly when the starting sample is very small or demonstrates few intact tumor cells. As many lung cancer patients have late stage disease and other comorbidities that make open surgical procedures hazardous, the least invasive biopsy technique with the highest potential specimen yield is now the preferred first diagnostic study. The MassARRAY® System, available in 24-, 96-, and 384-well formats, affords this capability.Increased early detection and personalized therapy for lung cancer have coincided with greater use of minimally invasive sampling techniques such as endobronchial ultrasound-guided biopsy (EBUS), endoscopic ultrasound-guided biopsy (EUS), and navigational biopsy, as well as thin needle core biopsies. An ideal validation method should be flexible and scalable in throughput to evaluate a varying number and type of markers. However, all genetic marker candidates – whether they are particular polymorphic loci, gene transcripts, or methylated regions – require further validation in order to advance to the next stage of utility and potentially lead to a molecular diagnostic test. Next-generation sequencing and genome-wide association studies have revolutionized the genetic landscape, leading to the discovery of genetic markers with potential relevance for personalized medicine and pharmacogenetics. Any combination of method, reagent, application, and sample type can be tested and analyzed using the MassARRAY System and software.The sensitivity of the Agena Bioscience chemistry allows a variety of sample types to be tested, from FFPE, to blood plasma, to whole genome amplified DNA.Choose from a variety of pre-configured reagent kits, or select one of our general reagent kits and use our assay design software to customize with your own primers and probes.Select the application best suited to your area of interest.The MassARRAY System simplifies the process of design and implementation of new testing paradigms in the laboratory. ![]() ![]() The MassARRAY® System by Agena Bioscience™ combines mass spectrometry, sensitive and robust chemistry, and advanced data analysis software to meet the assay design, validation, and routine testing needs of all genomic laboratories. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |